Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only.
In This Week’s Podcast
For the week ending May 13, 2022, John Mandrola, MD comments on the following news and features stories.
Mavacamten
Big news came from the US Food and Drug Administration (FDA) this month with their approval of the novel drug mavacamten, which I covered in the April 8 podcast. To briefly review, mavacamten is totally novel and first in its class. It is a reversible inhibitor of cardiac myosin. That is important in hypertrophic cardiomyopathy (HCM), as excess myosin-actin cross-bridge formation and dysregulation cause HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In short, it is a negative inotrope.
The FDA approval was based on the EXPLORER HCMtrial, published first in the Lancet in August 2020. EXPLORER was a placebo-controlled randomized control trial (RCT) conducted in 13 countries. Enrolled patients had a left ventricular outflow tract (LVOT) gradient of just over 50 mmHg and class 2 or 3 New York Heart Association
May 13, 2022 This Week in Cardiology Podcast
COMMENTARY
May 13, 2022 This Week in Cardiology Podcast
John M. Mandrola, MD
DisclosuresMay 13, 2022
Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only.
In This Week’s Podcast
For the week ending May 13, 2022, John Mandrola, MD comments on the following news and features stories.
Mavacamten
FDA Clears Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
Big news came from the US Food and Drug Administration (FDA) this month with their approval of the novel drug mavacamten, which I covered in the April 8 podcast. To briefly review, mavacamten is totally novel and first in its class. It is a reversible inhibitor of cardiac myosin. That is important in hypertrophic cardiomyopathy (HCM), as excess myosin-actin cross-bridge formation and dysregulation cause HCM. Mavacamten shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In short, it is a negative inotrope.
The FDA approval was based on the EXPLORER HCMtrial, published first in the Lancet in August 2020. EXPLORER was a placebo-controlled randomized control trial (RCT) conducted in 13 countries. Enrolled patients had a left ventricular outflow tract (LVOT) gradient of just over 50 mmHg and class 2 or 3 New York Heart Association
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: May 13, 2022 This Week in Cardiology Podcast - Medscape - May 13, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Chief Cardiology Correspondent
John M. Mandrola, MD
Clinical Electrophysiologist, Baptist Medical Associates, Louisville, Kentucky
Disclosure: John M. Mandrola, MD, has disclosed no relevant financial relationships.